Literature DB >> 25140961

Cancer of unknown primary site.

Gauri R Varadhachary1, Martin N Raber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25140961     DOI： 10.1056/NEJMra1303917

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  81 in total

1.  A 26-year-old Woman With Bilateral Leg Pain and Pruritus.

Authors:  S M Morell; Jerad M Gardner; L J Suva; C O Montgomery
Journal:  Clin Orthop Relat Res       Date:  2015-07-17       Impact factor: 4.176

2.  Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients.

Authors:  Yifei Ma; Wei Xu; Ruojing Bai; Yiming Li; Hongyu Yu; Chunshan Yang; Huazheng Shi; Jian Zhang; Jidong Li; Chenguang Wang; Jianru Xiao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-07       Impact factor: 9.236

Review 3.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 4.  Metastatic tumors to the jaws and mouth.

Authors:  Abraham Hirshberg; Raanan Berger; Irit Allon; Ilana Kaplan
Journal:  Head Neck Pathol       Date:  2014-11-20

5.  Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.

Authors:  Ibiayi Dagogo-Jack; David Fabrizio; Jochen Lennerz; Alexa B Schrock; Lauren Young; Mari Mino-Kenudson; Subba R Digumarthy; Rebecca S Heist; Siraj M Ali; Vincent A Miller; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2017-05-09       Impact factor: 15.609

6.  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

Authors:  Supriya K Saha; John D Gordan; Benjamin P Kleinstiver; Phuong Vu; Mortada S Najem; Jia-Chi Yeo; Lei Shi; Yasutaka Kato; Rebecca S Levin; James T Webber; Leah J Damon; Regina K Egan; Patricia Greninger; Ultan McDermott; Mathew J Garnett; Roger L Jenkins; Kimberly M Rieger-Christ; Travis B Sullivan; Aram F Hezel; Andrew S Liss; Yusuke Mizukami; Lipika Goyal; Cristina R Ferrone; Andrew X Zhu; J Keith Joung; Kevan M Shokat; Cyril H Benes; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2016-05-26       Impact factor: 39.397

7.  Molecular Profiles of Brain and Pulmonary Metastatic Disease in Cancer of Unknown Primary.

Authors:  Brianna R Bakow; Christopher P Elco; Mark LeGolvan; Don Dizon; Thomas A Ollila
Journal:  Oncologist       Date:  2020-04-20

8.  Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Authors:  Farshad Farshidfar; Siyuan Zheng; Marie-Claude Gingras; Yulia Newton; Juliann Shih; A Gordon Robertson; Toshinori Hinoue; Katherine A Hoadley; Ewan A Gibb; Jason Roszik; Kyle R Covington; Chia-Chin Wu; Eve Shinbrot; Nicolas Stransky; Apurva Hegde; Ju Dong Yang; Ed Reznik; Sara Sadeghi; Chandra Sekhar Pedamallu; Akinyemi I Ojesina; Julian M Hess; J Todd Auman; Suhn K Rhie; Reanne Bowlby; Mitesh J Borad; Andrew X Zhu; Josh M Stuart; Chris Sander; Rehan Akbani; Andrew D Cherniack; Vikram Deshpande; Taofic Mounajjed; Wai Chin Foo; Michael S Torbenson; David E Kleiner; Peter W Laird; David A Wheeler; Autumn J McRee; Oliver F Bathe; Jesper B Andersen; Nabeel Bardeesy; Lewis R Roberts; Lawrence N Kwong
Journal:  Cell Rep       Date:  2017-06-27       Impact factor: 9.423

9.  Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.

Authors:  Jennifer Shih; Babar Bashir; Karen S Gustafson; Mark Andrake; Roland L Dunbrack; Lori J Goldstein; Yanis Boumber
Journal:  J Natl Compr Canc Netw       Date:  2015-08       Impact factor: 11.908

Review 10.  CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

Authors:  Gregor Zaun; Martin Schuler; Ken Herrmann; Andrea Tannapfel
Journal:  Dtsch Arztebl Int       Date:  2018-03-09       Impact factor: 5.594
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.